Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease.
Brazikumab inhibits the binding of both recombinant and native IL-23 to its receptors stably expressed in COS cells with IC50s of 188 and 284 pM, respectively[1].Brazikumab inhibits the production of IFN-γ in NK cells stimulated by human native or recombinant IL-23 (in association with IL-18) with IC50s of 238 and 93 pM, respectively[1].
References:
[1]. Currò D, et, al. Frontiers in Drug Research and Development for Inflammatory Bowel Disease. Front Pharmacol. 2017 Jun 23;8:400.
[2]. Al-Bawardy B, et, al. Novel and Emerging Therapies for Inflammatory Bowel Disease. Front Pharmacol. 2021 Apr 14;12:651415.